PriceTargets.com logo

BioLife Solutions - BLFS Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $31.20
  • Forecasted Upside: 27.71%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$24.43 As of 02/7/2023 01:00 AM ET
▼ -1.59 (-6.11%)

This chart shows the closing price for BLFS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New BioLife Solutions Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BLFS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BLFS

Analyst Price Target is $31.20
▲ +27.71% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for BioLife Solutions in the last 3 months. The average price target is $31.20, with a high forecast of $34.00 and a low forecast of $29.00. The average price target represents a 27.71% upside from the last price of $24.43.

This chart shows the closing price for BLFS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 investment analysts is to buy stock in BioLife Solutions. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/16/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/14/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/12/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/13/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/11/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/9/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/8/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/7/2023

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/16/2022StephensLower Target$31.00N/A
8/15/2022CowenLower Target$29.00Low
5/17/2022B. RileyLower Target$48.00 ➝ $34.00Low
5/12/2022Maxim GroupLower Target$60.00 ➝ $30.00High
5/10/2022CowenLower Target$50.00 ➝ $32.00Medium
5/10/2022CowenLower Target$50.00 ➝ $32.00High
4/25/2022OppenheimerUpgradeMarket Perform ➝ OutperformHigh
3/2/2022B. RileyLower Target$67.00 ➝ $48.00Medium
11/12/2021Maxim GroupInitiated CoverageBuy$60.00High
11/11/2021B. RileyReiterated RatingBuyMedium
10/19/2021B. RileyInitiated CoverageBuy$61.00Low
9/2/2021Northland SecuritiesBoost TargetOutperform$55.00 ➝ $65.00High
8/13/2021KeyCorpBoost TargetOverweight$50.00 ➝ $60.00High
8/13/2021CowenBoost TargetOutperform$50.00 ➝ $64.00High
5/20/2021BenchmarkReiterated RatingBuy ➝ HoldMedium
5/14/2021BenchmarkDowngradeBuy ➝ HoldHigh
3/24/2021B. RileyBoost Target$35.50 ➝ $61.00Low
3/23/2021Maxim GroupBoost TargetBuy$40.00 ➝ $60.00High
3/23/2021StephensBoost TargetBuy ➝ Overweight$50.00 ➝ $55.00High
3/23/2021KeyCorpBoost TargetOverweight$40.00 ➝ $50.00High
3/23/2021BenchmarkUpgradeHold ➝ Buy$54.00High
3/18/2021B. RileyReiterated RatingBuyLow
12/28/2020Northland SecuritiesBoost Target$35.00 ➝ $55.00N/A
11/9/2020KeyCorpInitiated CoverageOverweight$40.00Low
10/19/2020B. RileyBoost Target$30.00 ➝ $35.00Low
9/23/2020B. RileyBoost Target$25.50 ➝ $30.00High
9/22/2020Maxim GroupBoost Target$26.00 ➝ $32.00High
9/22/2020Lake Street CapitalBoost TargetBuy$29.00 ➝ $35.00High
9/22/2020Northland SecuritiesBoost TargetOutperform$27.00 ➝ $35.00Medium
9/22/2020OppenheimerDowngradeOutperform ➝ Market PerformMedium
9/18/2020CowenInitiated CoverageOutperform$33.00High
8/11/2020BenchmarkDowngradeBuy ➝ Hold$21.00High
8/7/2020Maxim GroupInitiated CoverageBuy$26.00High
8/7/2020Northland SecuritiesReiterated RatingBuy$28.00Low
7/10/2020B. RileyBoost TargetBuy$20.00 ➝ $25.50Low
7/8/2020Maxim GroupBoost TargetBuy$18.00 ➝ $26.00Low
7/8/2020Northland SecuritiesReiterated RatingBuy$24.00 ➝ $28.00Low
6/4/2020HC WainwrightReiterated RatingBuy$17.00High
5/16/2020Maxim GroupReiterated RatingBuy$18.00High
5/15/2020StephensBoost TargetOverweight$23.00 ➝ $24.00High
5/6/2020OppenheimerReiterated RatingBuyHigh
5/5/2020HC WainwrightReiterated RatingBuy$17.00High
5/4/2020B. RileyLower TargetBuy$24.00 ➝ $22.00High
3/23/2020HC WainwrightLower TargetBuy$26.00 ➝ $17.00Medium
3/12/2020B. RileyLower TargetBuy$27.00 ➝ $24.00High
2/24/2020Lake Street CapitalInitiated CoverageBuy$25.00High
2/19/2020BenchmarkInitiated CoverageBuy$24.00High
2/6/2020B. RileyInitiated CoverageBuy$27.00High
1/7/2020StephensInitiated CoverageOverweight$23.00High
12/16/2019HC WainwrightReiterated RatingBuy$23.00 ➝ $26.00Low
11/20/2019OppenheimerInitiated CoverageOutperform$22.00High
9/17/2019Maxim GroupSet TargetBuy$26.00Low
9/4/2019Northland SecuritiesBoost TargetOutperform$18.00 ➝ $22.00High
8/9/2019Maxim GroupSet TargetBuy$24.00High
7/22/2019HC WainwrightInitiated CoverageBuy ➝ Buy$23.00High
7/9/2019Northland SecuritiesReiterated RatingBuy$18.00High
5/22/2019Maxim GroupSet TargetBuy$24.00Low
5/13/2019Northland SecuritiesReiterated RatingBuy$18.00Low
12/20/2018Janney Montgomery ScottUpgradeBuy$5.00Low
11/9/2018B. RileySet TargetBuy$22.00Low
10/3/2018B. RileySet TargetBuy ➝ Buy$22.00High
9/5/2018Maxim GroupReiterated RatingBuy$26.00High
8/14/2018B. RileySet TargetBuy$23.00Low
8/10/2018Northland SecuritiesReiterated RatingBuy$18.00Low
7/3/2018B. RileySet TargetBuy$19.00Low
6/7/2018B. RileyInitiated CoverageBuy$14.00Low
5/11/2018Maxim GroupBoost TargetBuy ➝ Buy$9.00 ➝ $12.00High
4/30/2018Maxim GroupSet TargetBuy$9.00Low
4/2/2018Maxim GroupReiterated RatingBuy$9.00High
3/19/2018Maxim GroupSet TargetBuy$8.00Low
3/12/2018Northland SecuritiesInitiated CoverageOutperformHigh
3/9/2018Maxim GroupSet TargetBuy$8.00High
(Data available from 2/7/2018 forward)

News Sentiment Rating

1.45 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/12/2022
  • 1 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/11/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/10/2022
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/10/2022
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/9/2022
  • 9 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/9/2022
  • 5 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/8/2023
  • 11 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/7/2023

Current Sentiment

  • 11 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

BioLife Solutions logo
BioLife Solutions, Inc. engages in the development, manufacture and marketing of bio preservation tools for cells and tissues. Its product offerings include proprietary hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs, generic blood stem cell freezing and cell thawing media products and custom product formulation and custom packaging services. The company was founded by Boris Rubinsky in 1987 and is headquartered in Bothell, WA.
Read More

Today's Range

Now: $24.43
Low: $23.75
High: $26.04

50 Day Range

MA: $21.02
Low: $16.95
High: $26.07

52 Week Range

Now: $24.43
Low: $10.40
High: $29.92

Volume

266,112 shs

Average Volume

345,589 shs

Market Capitalization

$1.04 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.86

Frequently Asked Questions

What sell-side analysts currently cover shares of BioLife Solutions?

The following equities research analysts have issued research reports on BioLife Solutions in the last year: B. Riley, Cowen Inc, Cowen Inc., Maxim Group, Oppenheimer Holdings Inc., Stephens, StockNews.com, and TheStreet.
View the latest analyst ratings for BLFS.

What is the current price target for BioLife Solutions?

5 Wall Street analysts have set twelve-month price targets for BioLife Solutions in the last year. Their average twelve-month price target is $31.20, suggesting a possible upside of 27.7%. B. Riley has the highest price target set, predicting BLFS will reach $34.00 in the next twelve months. Cowen Inc. has the lowest price target set, forecasting a price of $29.00 for BioLife Solutions in the next year.
View the latest price targets for BLFS.

What is the current consensus analyst rating for BioLife Solutions?

BioLife Solutions currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BLFS will outperform the market and that investors should add to their positions of BioLife Solutions.
View the latest ratings for BLFS.

What other companies compete with BioLife Solutions?

Other companies that are similar to BioLife Solutions include ViewRay, Outset Medical, Zynex, AxoGen and Edap Tms. Learn More about companies similar to BioLife Solutions.

How do I contact BioLife Solutions' investor relations team?

BioLife Solutions' physical mailing address is 3303 MONTE VILLA PARKWAY SUITE 310, BOTHELL WA, 98021. The medical equipment provider's listed phone number is (425) 402-1400 and its investor relations email address is [email protected] The official website for BioLife Solutions is www.biolifesolutions.com. Learn More about contacing BioLife Solutions investor relations.